JPWO2021195530A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021195530A5 JPWO2021195530A5 JP2022558017A JP2022558017A JPWO2021195530A5 JP WO2021195530 A5 JPWO2021195530 A5 JP WO2021195530A5 JP 2022558017 A JP2022558017 A JP 2022558017A JP 2022558017 A JP2022558017 A JP 2022558017A JP WO2021195530 A5 JPWO2021195530 A5 JP WO2021195530A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antagonist
- composition according
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 29
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 29
- 239000005557 antagonist Substances 0.000 claims 28
- 206010012438 Dermatitis atopic Diseases 0.000 claims 14
- 201000008937 atopic dermatitis Diseases 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 208000003251 Pruritus Diseases 0.000 claims 4
- 229940071643 prefilled syringe Drugs 0.000 claims 4
- 230000000699 topical effect Effects 0.000 claims 4
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 206010016946 Food allergy Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229940090047 auto-injector Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001224P | 2020-03-27 | 2020-03-27 | |
| US63/001,224 | 2020-03-27 | ||
| EP21315010 | 2021-01-28 | ||
| EP21315010.5 | 2021-01-28 | ||
| PCT/US2021/024419 WO2021195530A1 (en) | 2020-03-27 | 2021-03-26 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520676A JP2023520676A (ja) | 2023-05-18 |
| JPWO2021195530A5 true JPWO2021195530A5 (es) | 2024-04-03 |
Family
ID=75498103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558017A Pending JP2023520676A (ja) | 2020-03-27 | 2021-03-26 | Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230102151A1 (es) |
| EP (1) | EP4126951A1 (es) |
| JP (1) | JP2023520676A (es) |
| KR (1) | KR20220158821A (es) |
| CN (1) | CN115427450A (es) |
| AU (1) | AU2021244266A1 (es) |
| BR (1) | BR112022015363A2 (es) |
| CA (1) | CA3173173A1 (es) |
| IL (1) | IL296214A (es) |
| MX (1) | MX2022011730A (es) |
| WO (1) | WO2021195530A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102462039B1 (ko) | 2016-09-01 | 2022-11-02 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| EP4392450A1 (en) | 2021-08-23 | 2024-07-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| KR20240135618A (ko) * | 2021-12-30 | 2024-09-11 | 리제너론 파아마슈티컬스, 인크. | Il-4/il-13 길항제를 투여하여 아토피 행진을 약화시키는 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2382891T3 (es) | 2000-05-26 | 2012-06-14 | Immunex Corporation | Uso de anticuerpos IL-4R y sus composiciones |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| BRPI0416603A (pt) | 2003-11-07 | 2007-01-30 | Immunex Corp | anticorpo que se liga ao receptor interleucina-4 (il-4) humano |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| LT2769992T (lt) | 2006-10-02 | 2021-04-12 | Regeneron Pharmaceuticals, Inc. | Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| SG11201501011WA (en) | 2012-09-07 | 2015-03-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| RU2753869C2 (ru) * | 2016-02-19 | 2021-08-24 | Ридженерон Фармасьютикалз, Инк. | Способы повышения эффективности вакцины путем введения антагониста il-4r |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| EP3878868B1 (en) | 2018-11-09 | 2024-10-09 | Ajou University Industry-Academic Cooperation Foundation | Human antibody having high affinity to human il-4 receptor alpha, and use thereof |
-
2021
- 2021-03-26 AU AU2021244266A patent/AU2021244266A1/en active Pending
- 2021-03-26 IL IL296214A patent/IL296214A/en unknown
- 2021-03-26 JP JP2022558017A patent/JP2023520676A/ja active Pending
- 2021-03-26 WO PCT/US2021/024419 patent/WO2021195530A1/en active Application Filing
- 2021-03-26 MX MX2022011730A patent/MX2022011730A/es unknown
- 2021-03-26 US US17/907,070 patent/US20230102151A1/en active Pending
- 2021-03-26 EP EP21718786.3A patent/EP4126951A1/en active Pending
- 2021-03-26 CA CA3173173A patent/CA3173173A1/en active Pending
- 2021-03-26 CN CN202180024611.8A patent/CN115427450A/zh active Pending
- 2021-03-26 BR BR112022015363A patent/BR112022015363A2/pt unknown
- 2021-03-26 KR KR1020227037517A patent/KR20220158821A/ko active Search and Examination
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210130451A1 (en) | Treatment for rheumatoid arthritis | |
| EP4011915B1 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2019529560A5 (es) | ||
| RU2019111921A (ru) | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r | |
| EP3487881B1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2021502349A5 (es) | ||
| JP2023520676A (ja) | Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 | |
| JPWO2021026205A5 (es) | ||
| He et al. | New options for uveitis treatment | |
| JP2024016237A5 (es) | ||
| JPWO2019222055A5 (es) | ||
| JP2021147383A (ja) | アトピー性皮膚炎及び関連障害を処置するための方法 | |
| JPWO2021195530A5 (es) | ||
| WO2022258814A1 (en) | Methods for treating atopic dermatitis and related disorders | |
| WO2021191220A1 (en) | Methods for treating atopic dermatitis and related disorders | |
| RU2024107446A (ru) | Способы лечения атопического дерматита посредством введения антагониста il-4r | |
| RU2022105374A (ru) | Способы лечения атопического дерматита посредством введения антагониста il-4r | |
| RU2024105814A (ru) | Лечение атопического дерматита | |
| RU2024121393A (ru) | Способы ослабления атопического марша посредством введения антагониста il-4/il-13 | |
| RU2020140639A (ru) | Способы лечения атопического дерматита посредством введения ингибитора ил-4r | |
| NZ769607B2 (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
| Saco et al. | Biologics in allergic disease | |
| NZ769607A (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
| JP2019178153A (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |